Management Policies

Message from Leadership

Net sales, operating profit, and profit attributable to owners of the parent all reached historic highs.

Net sales rose, pushed up by favorable performance in all regions, including emerging markets.

Operating profit grew substantially, buoyed by higher gross profit stemming from the rise in net sales.

Nov. 2024

Kaoru Asano
President

In the first six months of the fiscal year ending March 31, 2025, the Sysmex Group achieved sales increases across all regions, buoyed by performance in emerging markets and other areas, in hematology* as well as other fields. Thanks to increased net sales and an improved cost of sales ratio, operating profit surged, and profit attributable to owners of the parent also increased. Year on year, net sales was up 14.0%, operating profit was up 31.6%, and profit attributable to owners of the parent was up 17.2%. At exchange rates prevailing one year earlier, net sales would have been up 8.0% and operating profit up 14.9%.

Looking at results by business, sales increased in the diagnostics business, centered on the hematology, hemostasis, and immunochemistry fields. In the hematology field, we benefited from favorable sales of the XR™-Series in Japan and EMEA, and the commencement of direct sales contributed to double-digit growth in reagent sales in Saudi Arabia. In the hemostasis field, the commencement of direct sales in EMEA, plus performance in India, Southeast Asia, and other parts of the AP region led to favorable results. In immunochemistry field, double-digit growth in sales of instruments and reagents in the AP region led to increased sales.

Steady adoption continued in the medical robotics business. We are becoming a clear presence in Japan, with a total of 64 units installed as of September 30, 2024. Following approval in Singapore, in August 2024 Medicaroid Corporation obtained sales approval in Malaysia, and we are steadily preparing to enter overseas markets.

For the fiscal year ending March 31, 2025, we have revised our full-year forecast for consolidated operating profit upward by ¥3.0 billion, bringing the full-year operating profit to ¥90 billion, owing to an improved cost of sales ratio. Our forecast for net sales and profit attributable to owners of the parent remains unchanged from the figures announced in May.

We maintain our initial dividend forecast for the year at ¥30 per share (interim and year-end dividends of ¥15 each).

■Assumed Full Year Exchange Rates for Fiscal Year ending March 31, 2025 (JPY)

	1USD	1EUR	1CNY
Announced November 2024	149.8	162.0	20.8
Announced May 2024	147.0	158.0	20.4
[Reference] Fiscal year ended March 31, 2024	144.6	156.8	20.1

* Hematology field: The field of in vitro diagnostics that determines whether precise testing is necessary by analyzing the number, type and size of red, white and other blood cells.

Back to "Management Policies"